Phase I/IIa study of immunization with a p16INK4a peptide combined with MONTANIDE ISA-51 VG in patients with advanced HPV-associated cancers

Trial Profile

Phase I/IIa study of immunization with a p16INK4a peptide combined with MONTANIDE ISA-51 VG in patients with advanced HPV-associated cancers

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs Human papillomavirus vaccine (Primary) ; Montanide ISA-51
  • Indications Anal cancer; Cervical cancer; Head and neck cancer; Human papillomavirus infections; Penile cancer
  • Focus Therapeutic Use
  • Acronyms VicOryx
  • Sponsors Oryx GmbH & Co
  • Most Recent Events

    • 07 Mar 2016 Results published in the Cancer
    • 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jun 2015 Immunogenicity and tolerability results (n=20) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top